AllianceBernstein’s CASI Pharmaceuticals CASI Stock Holding History

AllianceBernstein’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,440	Closed	-$131K	–	3337
2021 Q1	$131K	Hold	5,440	–	–	﹤0.01%	3126
2020 Q4	$160K	Sell	5,440 -190	-3%	-$4.13K	﹤0.01%	3044
2020 Q3	$86K	Sell	5,630 -1,590	-22%	-$29.9K	﹤0.01%	3089
2020 Q2	$181K	Buy	7,220 +1,320	+22%	+$28.7K	﹤0.01%	3021
2020 Q1	$120K	Buy	5,900 +1,020	+21%	+$24.3K	﹤0.01%	2917
2019 Q4	$151K	Hold	4,880	–	–	﹤0.01%	2979
2019 Q3	$163K	Buy	4,880 +280	+6%	+$8.99K	﹤0.01%	2988
2019 Q2	$147K	Buy	4,600 +740	+19%	+$23.6K	﹤0.01%	3022
2019 Q1	$111K	Buy	3,860 +1,520	+65%	+$53K	﹤0.01%	3000
2018 Q4	$94K	Buy	2,340 +850	+57%	+$32.2K	﹤0.01%	3001
2018 Q3	$70K	Buy	1,490 +290	+24%	+$20.2K	﹤0.01%	3103
2018 Q2	$99K	Buy	+1,200	New	+$81K	﹤0.01%	3053

Other funds holding CASI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AllianceBernstein's CASI Position: Q2 2021 in Review

AllianceBernstein sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 5,440 shares — an estimated $131K sold.

AllianceBernstein first reported a position in CASI in Q2 2018 and held it in 12 quarters. The position peaked at $181K in Q2 2020. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

AllianceBernstein reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 5,440 CASI Pharmaceuticals shares in Q2 2021, an estimated $131K.
AllianceBernstein first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 12 quarters.
AllianceBernstein's CASI Pharmaceuticals position peaked at $181K in Q2 2020.
68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.